Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 7/20 | 0.75 |
| ▸ | CNR1 | P21554 | 1/20 | 0.75 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.75 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.34 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1055232 | 0.94 | F2R (0.66) | F2RCNR1TMEM97FAAHTRPA1 | |
| SCHEMBL1050092 | 0.90 | F2R (0.60) | F2RCNR1TMEM97KMT2A | |
| SCHEMBL1055397 | 0.90 | F2R (0.60) | F2RCNR1TMEM97FAAHKMT2A | |
| SCHEMBL1055822 | 0.89 | F2R (0.60) | F2RCNR1TMEM97FAAHTRPA1 | |
| SCHEMBL1055662 | 0.89 | F2R (0.74) | F2RCNR1TMEM97FAAHTRPA1 | |
| SCHEMBL1054651 | 0.89 | F2R (0.59) | F2RCNR1TMEM97FAAHKMT2A | |
| SCHEMBL1054933 | 0.89 | F2R (0.59) | F2RCNR1TMEM97TRPA1KMT2A | |
| SCHEMBL1051879 | 0.89 | F2R (0.59) | F2RCNR1TMEM97FAAHKMT2A | |
| SCHEMBL1056313 | 0.88 | F2R (0.58) | F2RCNR1TMEM97TRPA1KMT2A | |
| SCHEMBL3755818 | 0.87 | F2R (0.70) | F2RCNR1TMEM97FAAHTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220563-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-30 | — | — | US | disclosed |
| US-20120220563-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-30 | — | — | US | disclosed |
| US-8084469-B2 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084469-B2 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084469-B2 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20110021489-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021489-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021489-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| WO-2010136144-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136144-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021489-A1 | SUBSTITUTED PIPERIDINES | VHL, PIR, PIGO | F2R 1339/4885CNR1 460/4885TMEM97 903/4885 |
| US-20120220563-A1 | Substituted piperidines | VHL, PIR, PIGO | F2R 1339/4885CNR1 460/4885TMEM97 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.